Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026

Section 2(b) and Section 2(c)(1): This provision requires a report on safety, dosing, and adverse event data from clinical trials evaluating emerging treatments like whole-mushroom psilocybin for post-traumatic stress disorder. This could benefit veterans and servicemembers by pushing the government to closely examine alternative therapies when standard treatments fail.

Section 2(c)(2): This requires an assessment of how trial data impacts suicide prevention strategies and identifies gaps in existing treatments. This is positive because it directly targets the severe risks of chronic impairment and suicidality associated with treatment-resistant post-traumatic stress disorder.

Section 2(c)(5): This provision assesses considerations to ensure continuity of care for members transitioning from military medical treatment facilities to the Veterans Health Administration. This is a helpful step to ensure that healthcare, safety monitoring, and clinical oversight are not disrupted when a servicemember leaves the military.

Section 2(a)(3) and Section 2(f)(2): The text notes that existing therapies are not effective for all patients, and the bill deals with investigational Schedule I substances and treatments like whole-mushroom psilocybin. Because these are still experimental investigational options, patients relying on them face uncertainties regarding actual efficacy and potential unknown adverse events until the research is fully evaluated.

Section 2(c)(3) and Section 2(c)(4): These sections require descriptions of complex legal and regulatory requirements for expanded access pathways involving Schedule I substances, alongside federal right-to-try pathways. Navigating these strict federal rules and coordination requirements between agencies like the Food and Drug Administration and the Drug Enforcement Administration could create bureaucratic hurdles or delays for individuals seeking immediate access to treatments.